QHRD107 + venetoclax + azacitidine

QHRD107 + venetoclax + azacitidine is a combination therapy under clinical investigation for the treatment of relapsed or refractory acute myeloid leukemia (AML). The regimen consists of three agents: 1. **QHRD107** – a potent, orally administered small molecule inhibitor of cyclin-dependent kinase 9 (CDK9), developed by Changzhou Qianhong Biopharma. It induces apoptosis and represses MCL1 expression in leukemia cells, showing high selectivity and cytotoxicity against malignant hematological cells[1][2][3][5][6]. 2. **Venetoclax** – an oral BCL2 inhibitor approved for various hematologic malignancies, marketed as Venclexta. 3. **Azacitidine** – a hypomethylating agent that incorporates into DNA and RNA to inhibit DNA methyltransferase, marketed as Vidaza. The combination is being evaluated in phase IIa clinical trials for its safety and efficacy in patients with relapsed/refractory AML[2][4]. The rationale is to synergistically induce leukemic cell death by targeting complementary anti-apoptotic pathways.

Brand names

Venclexta (for venetoclax)Vidaza (for azacitidine)

Other names

QHRD107 + venetoclax + azacitidine107VA regimen